Paul M. Maciocia

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Journal: Haematologica
Published: November 04, 2025

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia.

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia.

Journal: Science translational medicine
Published: April 16, 2025

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

Journal: British journal of haematology
Published: March 01, 2025

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas as mechanism of primary resistance to TRBC-directed CAR T cell therapies.

Journal: Nature communications
Published: October 13, 2024

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

Journal: Hematological oncology
Published: September 22, 2024

Single-centre experience of implementing physiotherapist-led prehabilitation for chimeric antigen receptor T cell therapy.

Single-centre experience of implementing physiotherapist-led prehabilitation for chimeric antigen receptor T cell therapy.

Journal: EJHaem
Published: June 12, 2024

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Journal: Blood advances
Published: June 11, 2024

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Journal: Nature medicine
Published: January 18, 2024

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.

Journal: Blood cancer journal
Published: December 01, 2023

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Journal: Nature communications
Published: March 21, 2022

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia.

Journal: Blood
Published: August 17, 2021

Chimeric antigen receptor T cells for gamma-delta T cell malignancies.

Chimeric antigen receptor T cells for gamma-delta T cell malignancies.

Journal: Leukemia
Published: April 07, 2021
Showing 1-12 of 18

Last Updated: 09/26/2026